EU/3/17/1900: Orphan designation for the treatment of myelodysplastic syndromes



On 23 August 2017, orphan designation (EU/3/17/1900) was granted by the European Commission to Apogenix AG, Germany, for asunercept for the treatment of myelodysplastic syndromes.

Key facts

Active substance
Medicine name
Intended use
Treatment of myelodysplastic syndromes
Orphan designation status
EU designation number
Date of designation

Apogenix GmbH
Im Neuenheimer Feld 584
69120 Heidelberg

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Update history

September 2023The sponsor’s name was changed from Apogenix AG to Apogenix GmbH.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating